Pulmonary Drug Delivery Systems Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product, Indication, Distribution Channel, End User, and Geography

Description

The pulmonary drug delivery systems market size is expected to grow from US$ 49.71 billion in 2023 to US$ 73.14 billion by 2031; the market is projected to register a CAGR of 4.9% during 2023-2031.

Pulmonary drug delivery refers to the technologies and methods used to deliver medications directly into the lungs. These systems are aimed at targeting the delivery of aerosols directly to epithelial cells and respiratory epithelium by means of inhalation. These systems take advantage of the lung's large surface area, thin epithelial layer, and rich blood supply to facilitate rapid and efficient absorption of medications. The pulmonary drug delivery systems market growth is attributed to the increasing burden of respiratory diseases and growing strategic initiatives by companies. However, regulatory issues associated with the approval of pulmonary drug delivery systems hinder the growth of the pulmonary drug delivery systems market.

Recently, various initiatives and measures have been taken to create awareness and educate people regarding respiratory diseases, prompting patients to access suitable medications and treatments for such conditions. Cipla has a public service initiative called Breathefree for people with chronic airway diseases. Berok Zindagi's program seeks to enable asthmatics to reach their true potential and lead lives that are unstoppable with the use of an inhaler. Berok Zindagi has been crafted as a tool to arm consumers with all the information they require to embrace inhalers without reluctance and confront the stigma associated with inhalation therapy. By using multilingual and multimedia educational resources to raise awareness about illnesses and inhalers, educators ensure patient counseling. Through the efforts of 600+ Breathefree Educators and 5600+ doctors, the Breathefree Clinic service serves over 1,25,000+ respiratory patients throughout India.

CDC's National Asthma Control Program also provides funds for educating patients with asthma to receive education regarding their condition. Thus, such initiatives are likely to increase awareness about respiratory diseases, offering new opportunities for the growth of the pulmonary drug delivery systems market.

Distribution Channel-Based Insights

Based on distribution channel, the pulmonary drug delivery systems market is categorized into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment held a significant pulmonary drug delivery systems market share in 2023. In addition, the e-commerce segment is expected to register the highest CAGR during the forecast period. Hospital pharmacies are specialized pharmacies integrated into healthcare centers such as hospitals, clinics, poison control centers, residential care facilities' drug information centers, and drug dependency facility centers. Capacities to support the storage of extensive stocks, availability of various medicines on the spot, and reimbursement on the drugs purchased under healthcare plans are the primary benefits conferred by these pharmacies. Hospital pharmacies are not retail establishments; they typically provide medications for hospitalized patients. Therefore, they don't provide prescription services to the public. Hence, the ease of availability of specialized therapeutics contributes to the inclination of patients toward hospital pharmacies, which is positively influencing the pulmonary drug delivery systems market growth.

End User-Based Insights

Based on end user, the pulmonary drug delivery systems market is categorized into hospitals & clinics and homecare. The hospitals & clinics segment held a significant pulmonary drug delivery systems market share in 2023. The homecare segment is estimated to register a higher CAGR during 2023-2031.

The US Food and Drug Administration, the World Health Organization, and the Centers for Disease Control and Prevention are among the primary and secondary sources referred to while preparing the pulmonary drug delivery systems market report.

Product Code: TIPHE100001256

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Pulmonary Drug Delivery Systems Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Pulmonary Drug Delivery Systems Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Pulmonary Drug Delivery Systems Market - Global Market Analysis

6.1 Pulmonary Drug Delivery Systems - Global Market Overview
6.2 Pulmonary Drug Delivery Systems - Global Market and Forecast to 2031

7. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million) - By Product, 2021-2031

7.1 Overview
7.2 Dry Powder Inhalers
7.3 Metered Dose Inhalers
7.4 Nebulizers

8. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million) - By Indication, 2021-2031

8.1 Overview
8.2 Chronic Obstructive Pulmonary Disease
8.3 Asthma
8.4 Cystic Fibrosis
8.5 Others

9. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million) - By Distribution Channel, 2021-2031

9.1 Overview
9.2 Hospital Pharmacies
9.3 Retail Pharmacies
9.4 E-commerce

10. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million) - By End User, 2021-2031

10.1 Overview
10.2 Hospitals and Clinics
10.3 Homecare

11. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

11.1 North America
- 11.1.1 North America Pulmonary Drug Delivery Systems Market Overview
- 11.1.2 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts to 2031
- 11.1.3 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By Product
- 11.1.4 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By Indication
- 11.1.5 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By Distribution Channel
- 11.1.6 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By End User
- 11.1.7 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By Countries
  - 11.1.7.1 United States Pulmonary Drug Delivery Systems Market
    - 11.1.7.1.1 United States Pulmonary Drug Delivery Systems Market, by Product
    - 11.1.7.1.2 United States Pulmonary Drug Delivery Systems Market, by Indication
    - 11.1.7.1.3 United States Pulmonary Drug Delivery Systems Market, by Distribution Channel
    - 11.1.7.1.4 United States Pulmonary Drug Delivery Systems Market, by End User
  - 11.1.7.2 Canada Pulmonary Drug Delivery Systems Market
    - 11.1.7.2.1 Canada Pulmonary Drug Delivery Systems Market, by Product
    - 11.1.7.2.2 Canada Pulmonary Drug Delivery Systems Market, by Indication
    - 11.1.7.2.3 Canada Pulmonary Drug Delivery Systems Market, by Distribution Channel
    - 11.1.7.2.4 Canada Pulmonary Drug Delivery Systems Market, by End User
  - 11.1.7.3 Mexico Pulmonary Drug Delivery Systems Market
    - 11.1.7.3.1 Mexico Pulmonary Drug Delivery Systems Market, by Product
    - 11.1.7.3.2 Mexico Pulmonary Drug Delivery Systems Market, by Indication
    - 11.1.7.3.3 Mexico Pulmonary Drug Delivery Systems Market, by Distribution Channel
    - 11.1.7.3.4 Mexico Pulmonary Drug Delivery Systems Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

11.2 Europe
- 11.2.1 Germany
- 11.2.2 France
- 11.2.3 Italy
- 11.2.4 Spain
- 11.2.5 United Kingdom
- 11.2.6 Rest of Europe
11.3 Asia-Pacific
- 11.3.1 Australia
- 11.3.2 China
- 11.3.3 India
- 11.3.4 Japan
- 11.3.5 South Korea
- 11.3.6 Rest of Asia-Pacific
11.4 Middle East and Africa
- 11.4.1 South Africa
- 11.4.2 Saudi Arabia
- 11.4.3 U.A.E
- 11.4.4 Rest of Middle East and Africa
11.5 South and Central America
- 11.5.1 Brazil
- 11.5.2 Argentina
- 11.5.3 Rest of South and Central America

12. Industry Landscape

12.1 Mergers and Acquisitions
12.2 Agreements, Collaborations, Joint Ventures
12.3 New Product Launches
12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

13.1 Heat Map Analysis by Key Players
13.2 Company Positioning and Concentration

14. Pulmonary Drug Delivery Systems Market - Key Company Profiles

14.1 AstraZeneca plc
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments

Note - Similar information would be provided for below list of companies

14.2 Boehringer Ingelheim International GmbH
14.3 GlaxoSmithKline plc
14.4 Novartis AG
14.5 Koninklijke Philips NV
14.6 Cipla Inc.
14.7 OMRON Corp.
14.8 PARI GmbH
14.9 Glenmark Pharmaceuticals
14.10 Gilbert Technologies

15. Appendix

15.1 Glossary
15.2 About The Insight Partners
15.3 Market Intelligence Cloud